Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
6
Recruiting, industry sponsors, Psychiatry, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed272
6 trials
Showing 1 to 6, recently updated first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07221877 · 60 participants (planned) · Start Jan 20, 2026 · Primary completion Dec 30, 2027
Drug: Xanomeline/trospium chloride · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Chino, California · 16 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT04781140 · 286 participants (planned) · Start Mar 19, 2024 · Primary completion Jan 2028
Drug: 100mg SPN-812; Placebo · For: Attention-Deficit/Hyperactivity Disorder
Sites: Saraland, Alabama; Fayetteville, Arkansas; Little Rock, Arkansas · 54 sites in all
Vanda PharmaceuticalsIndustry
NCT05648591 · 100 participants (planned) · Start May 24, 2023 · Primary completion Dec 31, 2028
Drug: Iloperidone · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Denver, Colorado · 11 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105111 · 100 participants (planned) · Start Aug 29, 2025 · Primary completion Jun 2028
Drug: Valbenazine · For: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder and 2 more
Sites: Bryant, Arkansas; Chino, California; Fresno, California · 19 sites in all
- Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment DisordersPivotal-lookingRecruiting
Valenta Pharm JSCIndustry
NCT06843044 · 250 participants (planned) · Start Jan 13, 2025 · Primary completion Dec 31, 2027
Drug: Ranquilon; Afobazole · For: Anxiety; Neurasthenia; Adjustment Disorders
Sites: Engel's, Russia; Moscow, Russia; Saint Petersburg, Russia · 6 sites in all
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT06223880 · 350 participants (planned) · Start Dec 27, 2023 · Primary completion Mar 2026
Drug: AXS-05; Bupropion · For: Major Depressive Disorder
Sites: Bellflower, California; Lafayette, California; Oceanside, California · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.